Literature DB >> 21135550

Failure of primary percutaneous angioplasty and stenting in the prevention of ischemia in Moyamoya angiopathy.

Nadia Khan1, Robert Dodd, Michael P Marks, Teresa Bell-Stephens, Joli Vavao, Gary K Steinberg.   

Abstract

BACKGROUND: Moyamoya disease (MMD) is an idiopathic progressive arteriopathy affecting the proximal intracranial vasculature. To date only 4 case reports on intracranial angioplasty or stenting as treatment of this disease exist. We present 5 adult patients with MMD who failed angioplasty and/or stenting who remained symptomatic despite endovascular treatment or presented with recurrent symptoms and recurrence of stenosis/occlusion on angiography requiring subsequent extracranial-intracranial revascularization.
METHODS: Five adult MMD patients who underwent endovascular treatment with angioplasty or stenting were referred for further evaluation and treatment from outside hospitals. Data were collected from clinical referral notes and angiograms or reports. All patients underwent repeat 6-vessel cerebral angiography to assess the extent of disease and results of prior endovascular treatment.
RESULTS: Six endovascular procedures were performed in all 5 patients. Internal carotid artery (ICA) balloon angioplasty and Wingspan stenting was performed in 2 patients (3 arteries). One patient had ICA-M1 angioplasty without stenting. Two patients had M1 angioplasty and Wingspan stenting. All patients developed repeat transient ischemic attacks following treatment attributable to the vascular territories of endovascular treatment. Repeat endovascular treatment was performed in 3 patients at a mean of 4 months (range = 2-6). Two went on to a third endovascular treatment due to progression of disease in the angioplastied/stented vessel. The average time of symptom recurrence after initial endovascular therapy was 1.8 months (0-4 months). Follow-up angiography when referred to our institution demonstrated 70-90% instent restenosis of the stented vessel in 3 and occlusion in 1 patient. Due to persistence of symptoms cerebral revascularization was performed in all patients.
CONCLUSION: MMD is a progressive angiopathy. Angioplasty and stenting may temporarily improve the cerebral blood flow and decrease cerebral ischemic events but do not appear to be durable nor provide long-term prevention against future ischemic events.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 21135550     DOI: 10.1159/000320253

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  14 in total

Review 1.  Surgical Treatment of Adult Moyamoya Disease.

Authors:  Si Un Lee; Chang Wan Oh; O-Ki Kwon; Jae Seung Bang; Seung Pil Ban; Hyoung Soo Byoun; Tackeun Kim
Journal:  Curr Treat Options Neurol       Date:  2018-05-28       Impact factor: 3.598

Review 2.  Recent advances in moyamoya disease: pathophysiology and treatment.

Authors:  Annick Kronenburg; Kees P J Braun; Albert van der Zwan; Catharina J M Klijn
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

3.  Moyamoya arteriopathy.

Authors:  Edward R Smith
Journal:  Curr Treat Options Neurol       Date:  2012-12       Impact factor: 3.598

Review 4.  Endovascular treatment of symptomatic moyamoya.

Authors:  Bradley A Gross; Ajith J Thomas; Kai U Frerichs
Journal:  Neurosurg Rev       Date:  2014-04-03       Impact factor: 3.042

5.  2021 Japanese Guidelines for the Management of Moyamoya Disease: Guidelines from the Research Committee on Moyamoya Disease and Japan Stroke Society.

Authors:  Miki Fujimura; Teiji Tominaga; Satoshi Kuroda; Jun C Takahashi; Hidenori Endo; Kuniaki Ogasawara; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2022-02-22       Impact factor: 2.036

6.  Adult Moyamoya Disease: A Burden of Intracranial Stenosis in East Asians?

Authors:  Oh Young Bang; Sookyung Ryoo; Suk Jae Kim; Chang Hyo Yoon; Jihoon Cha; Je Young Yeon; Keon Ha Kim; Gyeong-Moon Kim; Chin-Sang Chung; Kwang Ho Lee; Hyung Jin Shin; Chang-Seok Ki; Pyoung Jeon; Jong-Soo Kim; Seung Chyul Hong
Journal:  PLoS One       Date:  2015-06-30       Impact factor: 3.240

7.  Specific Shrinkage of Carotid Forks in Moyamoya Disease: A Novel Key Finding for Diagnosis.

Authors:  Satoshi Kuroda; Daina Kashiwazaki; Naoki Akioka; Masaki Koh; Emiko Hori; Manabu Nishikata; Kimiko Umemura; Yukio Horie; Kyo Noguchi; Naoya Kuwayama
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-09-15       Impact factor: 1.742

Review 8.  Moyamoya Disease and Spectrums of RNF213 Vasculopathy.

Authors:  Oh Young Bang; Jong-Won Chung; Dong Hee Kim; Hong-Hee Won; Je Young Yeon; Chang-Seok Ki; Hyung Jin Shin; Jong-Soo Kim; Seung Chyul Hong; Duk-Kyung Kim; Akio Koizumi
Journal:  Transl Stroke Res       Date:  2019-10-24       Impact factor: 6.829

9.  Intracranial stenting using a drug-eluting stent for moyamoya disease involving supraclinoid ICA: a case report.

Authors:  Tackeun Kim; O-Ki Kwon; Chang Wan Oh; Jae Seung Bang; Gyojun Hwang; Young-Jin Lee
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-07       Impact factor: 1.742

10.  Emergency superficial temporal artery to middle cerebral artery bypass after intravenous recombinant tissue plasminogen activator administration for acute cerebral ischemia in a patient with moyamoya disease.

Authors:  Sadaharu Tabuchi; Sadao Nakajima; Yutaka Suto; Hiroyuki Nakayasu
Journal:  Case Rep Neurol       Date:  2013-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.